

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF  
06 AUG 22 AM 1

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name  The Duberstein Group Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported  2100 Pennsylvania Ave. NW Suite 500 Washington DC 20037 USA			
3. Principal place of business (if different than line 2)  City State/Zip or Country			
4a. Contact Name	b. Telephone number	c. E-mail	5. Senate ID #
Mr. Michael S. Berman	202-728-1100	mberman@dubersteingroup.com	12675-
7. Client Name <input type="checkbox"/> Self	Novartis Vaccines & Diagnostics, Inc.		6. House ID # 31811052

**TYPE OF REPORT** 8. Year 2006 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying Activities

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>20,000</u>  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>EXPENSES</b> relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> ⇨ \$ _____  <b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options: <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code

0000230750

Signature Michael S Berman Date 8/10/2006

Digitally signed by Michael S Berman  
DN: CN = Michael S Berman, C = US, O = DST ACES Business  
Representative, OU = ACES TrustID Business Certificate  
Date: 2006.08.10 16:30:53 -0400

01

Printed Name and Title Michael S. Berman, President

LD-2DS (Rev. 4.04)

✓ Page 1

Registrant Name The Duberstein Group Inc.

Client Name Novartis Vaccines & Diagnostics, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

Flu vaccine issues, including liability, appropriations, and avian flu -- HR 4939, Emergency Supplemental Appropriations Act for Defense, the Global War on Terror, and Hurricane Recovery, 2006.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives; Senate; The White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Berman	
Steven Champlin	
Kenneth Duberstein	
Henry Gandy	
Daniel Meyer	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

0000230751

Signature \_\_\_\_\_ Date 8/10/2006

Printed Name and Title Michael S. Berman, President

---

LD-2DS (Rev. 4.04)

Page 2

Registrant Name The Duberstein Group Inc. Client Name Novartis Vaccines & Diagnostics, Inc.

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State/Zip \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Owner's percent client
Novartis Corp.	Lichstrasse 35 Basel CH	Basel CH	\$0	10

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, cli affiliated organization

0000230752

Signature \_\_\_\_\_ Date 8/10/2006

Printed Name and Title Michael S. Berman, President

